Take a look at our year as told by the numbers to see a snapshot of the breakthrough scientific discoveries and important work happening at CCR.
- 234 Open Clinical Trials
- 45 New Clinical Trials
- 1,547 New Patients
- 236 Principal Investigators
- 11 New Faculty Recruits
- 7 Newly Tenured Investigators
- 345 Staff Scientists/Staff Clinicians
- ~500 Technical Lab Staff
- ~800 Postdoctoral/Clinical Fellows
- 327 Postbaccalaureate/Predoctoral Students
- >1,000 Articles in Peer-Reviewed Journals
- 47 Technology Facilities and Platforms
Technology Transfer Activities
- 70 New Employee Invention Reports
- 61 Issued U.S. Patents
- 28 New Cooperative Research and Development Agreements (CRADAs)
- 7 New Clinical CRADAs
- 183 Active CRADAs
- 87 Clinical CRADAs
- 9 Umbrella CRADAs
- 17 New Clinical Trial Agreements (CTAs)
- 88 Active CTAs
- 110 New Licenses for CCR Technologies
- 559 Active Licenses
- 2 FDA Approvals
- 1 FDA Breakthrough Drug Designation
- 1 FDA Orphan Drug Designation
The NCI Technology Transfer Center (TTC) works to enable and guide collaboration, invention development and licensing to advance today’s discoveries into tomorrow’s medical care. The TTC supports technology development activities for NCI in therapeutics, diagnostics, research tools, vaccines, devices and software, and facilitates partnerships with outside organizations so that NCI discoveries can reach the public in a timely manner.
For information on licensing and co-development opportunities, contact the TTC Invention Development and Marketing Unit (ncitechtransfer@mail.nih.gov), or visit techtransfer.cancer.gov for more information. Numbers are for FY2020.